Genetically engineered mouse models (GEMMs) that recapitulate the major genetic drivers in pancreatic ductal adenocarcinoma (PDAC) have provided unprecedented insights into the pathogenesis of this lethal neoplasm. Nonetheless, generating an autochthonous model is an expensive, time consuming and labor intensive process, particularly when tissue specific expression or deletion of compound alleles are involved. In addition, many of the current PDAC GEMMs cause embryonic, pancreas-wide activation or loss of driver alleles, neither of which reflects the cognate human disease scenario. The advent of CRISPR/Cas9 based gene editing can potentially circumvent many of the aforementioned shortcomings of conventional breeding schema, but ensuring the efficiency of gene editing in vivo remains a challenge. Here we have developed a pipeline for generating PDAC GEMMs of complex genotypes with high efficiency using a single "workhorse" mouse strain expressing Cas9 in the adult pancreas under a p48
INTRODUCTION:
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal cancers known, due to the absence of reliable early diagnosis and the absence of effective therapeutic regimens [1] . It is currently the third leading cause of cancer worldwide and is projected to become second leading cause of cancer in the United States by 2030. The median 5-year survival rate of PDAC is only 9% [2] , and underscores the need for developing new approaches in understanding the molecular mechanisms underlying the disease.
The advent of next generation sequencing (NGS) and its application as part of large publicly funded efforts such as The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) has identified a huge catalogue of genes that are altered in PDAC [3, 4] , although in many instances, particularly with low frequency mutations, the functional consequences of the alterations remain unknown. The definitive evidence for gene perturbation in carcinogenesis is typically obtained via autochthonous models, which in the context of PDAC, is exemplified by expression of a mutant Kras allele in the pancreas alongside one or more cooperating mutations [5] . First developed in 2003, PDAC GEMMs have dramatically accelerated our understanding of the molecular pathogenesis of this neoplasm, including how the genetic background of the cancer impacts the tumor microenvironment (TME) and resulting immune response [6] [7] [8] . In contrast to cell line or patient-derived xenograft (PDX) models, autochthonous models harbor the precursor lesions observed in the multistep progression of PDAC, as well as the stroma-dense TME observed in the corresponding human disease [9] [10] [11] .
Although autochthonous models have been instrumental in our understanding the molecular underpinnings of PDAC, the conventional Cre-based recombinatorial models do not faithfully mimic adult onset human PDAC due to their inherent limitation of inducing Ras activation and cooperating gene alteration(s) in every epithelial cell of the pancreas during development. In some respects, the conventional models are more analogous to "familial" PDAC where every cell in the pancreas is predisposed to neoplasia due to a germline anomaly (for example, CDKN2A/p16), and cancers arise due to stochastic bi-allelic gene inactivation [12, 13] . In addition to this conceptual limitation, conventional Cre-mediated recombinatorial models are also hindered by time, labor and expenses required for generating appropriate numbers of colonies, especially with complex genotypes where the "pups" of interest might only be a minor fraction of the litter. A timeframe of 12-18 months for completing the breeding of complex mouse genotypes is not unusual in the field. Novel platforms that bypass the pancreas-wide embryonic expression of mutant Kras and loss of cooperating alleles, while also greatly improving the efficiency of model generation would be a significant advancement in the preclinical arena.
Recently, the RNA-guided endonuclease Cas9 from microbial type II CRISPR (clustered regularly interspaced short palindromic repeat) system has emerged as a powerful tool for genome engineering in mammalian cells [14] [15] [16] , including somatic cell editing in a variety of mouse organs that includes brain, lung, liver and pancreas [17] [18] [19] [20] [21] . CRISPR/Cas9 can be targeted to the desired genomic loci by using programmable 20-bp single guide RNAs (sgRNAs) to generate DNA double stranded breaks which induce genome editing via one of the two DNA damage repair pathways: non homologous end-joining (NHEJ) resulting in insertion-deletion (INDELs), or homology directed repair (HDR) resulting in precise sequence substitution in the presence of a repair template [22] [23] [24] [25] . The multiplexing abilities of gene editing by combining multiple sgRNAs to the Cas9 provides this programmable nuclease system with a unique advantage for conducting in vivo combinatorial gene editing, especially in the context of developing autochthonous cancer models [21] . There have been several approaches used for delivering CRISPR/Cas9 in vivo in murine pancreatic cells, including lentivirus and plasmid based transfection [26, 27] , although many of these vectors are hindered by low efficiency of multiplexed gene editing and risk of on-target recombination in unintended cell types or tissues [28] . In recent years, adeno-associated virus (AAV) vectors, in particular, have been increasingly utilized for in vivo delivery approaches of sgRNAs due to their efficiency, lack of inherent pathogenicity and strong safety profile [29] [30] [31] [32] .
In order to generate a "workhorse" model of genetically engineered mice that develop PDAC with a variety of complex genotypes, we have developed a simple injection method by employing AAV-based delivery of sgRNAs cargo to the pancreas of adult mice, where Cas9 activity is restricted to the p48-expressing acinar compartment [33] . Our model overcomes several challenges of the current Cre-based models, including the introduction of mutant alleles in a subset of adult pancreatic epithelial cells (rather than pancreas-wide embryonic expression), and the use of a single "workhorse" mouse genotype (p48-Cre; LSL-Cas9) from which cancers harboring multiple complex genotypes can be readily generated through somatic gene editing, thus greatly increasing efficiency. Importantly, in contrast to some of the recently described CRISPR/Cas9-mediated PDAC models that require an oncogenic Kras G12D allele in the pancreas on which cooperating mutations are then introduced by CRISPR/Cas9 [26, 27] , our method dispenses with the need for a constitutive Kras G12D allele, by including a mutant Kras G12D template in the delivery cargo that recombines with, and replaces, the endogenous wild type allele through HDR.
MATERIALS AND METHODS:
Generation of pancreas specific Cre-dependent Cas9 mice:
Conditional Cas9 mice (Rosa26-LSL-Cas9) was obtained from the Jackson Laboratory and was crossed with pancreas specific p48-Cre mice in order to generate experimental p48-Cre; LSL-Cas9 mice. The following primers were used to genotype Cas9 (Cas9_Common-S 5'-AAGGGAGCTGCAGTGGAGTA-3'; Cas9_Wild-AS 5'-CCGAAAATCTGTGGGAAGTC-3';
Cas9_Mut-AS 5'-CGGGCCATTTACCGTAAGTTAT-3') and p48-Cre (ptf1a_Fw 5'-AACCAGGCCCAGAAGGTTAT-3'; ptf1a_Rv 5'-TCAAAGGGTGGTTCGTTCTC-3'; ptf1a_Cre_Fw 5'-ATAGGCTACCTGGCCATGCCC-3'; ptf1a_Cre_Rv 5'-CGGGCTGCAGGAATTCGTCG-3').
CRISPR sgRNA design:
CRISPR sgRNAs for Kras, Trp53 and Lkb1 have been previously described [19] . Genomic sequence for Arid1a gene was downloaded from UCSC genome browser and sgRNA cassette was generated using the CRISPR design tool (http://crispr.mit.edu).
AAV vector plasmids:
The AAV-KPL plasmid (AAV: ITR-U6-sgRNA (Kras)-U6-sgRNA (p53)-U6-sgRNA (LKB1)-pEFS-RLUC-2A-Cre-shortPA-KrasG12D_HDRDonor-ITR) was obtained from Addgene.
AAV-KPLΔCre was generated by removing the Cre sequence from AAV-KPL by digesting with Nhe1 and HindIII followed by ligation. AAV-KPΔCre was generated by digesting AAV-KPLΔCre with Kpn1 and Xba1 and followed by ligation. AAV-KΔCre was made by digesting AAV-KPLΔCre with BamH1 and Kpn1, and followed by ligation. To construct AAV-KPAΔCre, first the sgRNA for mouse Arid1a exon3 was cloned into the pX459 (pSpCas9 (BB)-2A-Puro) vector, then the whole segment containing the U6 promoter, Arid1a sgRNA with primers containing Xba1 and Kpn1 sites was PCR amplified. Finally, AAV-KPLΔCre was digested with Xba1 and Kpn1 to release the Lkb1 CRISPR containing unit following which the entire amplicon containing Arid1a CRISPR was ligated to generate AAV-KPAΔCre. AAV-KAΔCre was made by digesting AAV-KPAΔCre with BamH1 and Xba1 and re-ligated. All of the AAV vector constructs were sequence verified before virus production. All vector constructs are readily available from the authors upon request (the schematic of the constructs are shown in Supplementary Fig. 1A ).
AAV vector production:
Human Embryonic Kidney 293T (HEK293T) cells were used for AAV production. HEK293T GCATTGGAAAAGAATCCTGGGTCC) on a BIO-RAD CFX96.
Surgical procedure and direct injection:
100 μ l of PBS containing AAV-CRISPR sequences was injected into the pancreatic tail using 29 G needle (BD Biosciences) through left subcostal laparotomy under inhaled anesthesia. Leakage was not observed in any mice during the procedure. After the injection, the pancreas and spleen was carefully returned into the peritoneal cavity and the abdomen was closed using 4-0 Vicryl (Ethicon) and skin staplers. All the mice were monitored at least once a week by abdominal palpation and abdominal ultrasound to investigate the entire pancreas was performed every 4 weeks using the Vevo 2100 (Fujifilm). Moribund mice with pancreatic tumors were euthanized by cervical dislocation and carbon dioxide inhalation according to the IACUC protocol. The assessment of primary tumor, intraperitoneal dissemination and distant metastases performed were based on both gross findings at necropsy and by histopathological examination. Any surviving mice at 100 days (~ 3 months post injection) were then euthanized and the Pancreata harvested for histopathological examination.
T7 Endonuclease Gene editing assay:
Genomic DNA was isolated from tumor samples using the Qiagen genomic DNA isolation kit.
Subsequently ~400bp of genomic fragment encompassing the CRISPR targeted cleavage site was PCR amplified with high fidelity Taq polymerase. Approximately 200ng of purified PCR product was used for each T7 endonuclease assay. Briefly, 2ul NEBuffer 2, 200ng of purified PCR product and dH2O was added to a total of 19ul in a PCR tube. The hybridization reaction was run as follows: 5min, 95C; ramp down to 85C at -2C/s; ramp down to 25C at -0.1C/s; hold at 4C. We then added 1ul (10U) T7 endo I and incubated at 37C for 15min. The reaction was stopped by adding 2ul of 0.25M EDTA and loaded immediately on a 1.5% agarose gel.
Immunofluorescence:
Pancreata were harvested from the moribund mice due to tumor burden at different time point with maximum harvesting time around ~100 days. Pancreata were fixed in 4% paraformaldehyde, followed by standard paraffin embedding. Tissue was then cut into 5uM sections. Incubations with primary antibodies were performed overnight at 4 0 C using standard techniques in PBS containing 0.2% Triton and 10% FBS using the following antibodies or probes: mouse anti-E-Cadherin (BD Transduction 610181, 1:50); rabbit anti-Sox9 (Millipore AB5535, 1:1000); hamster anti-Muc1 (Thermo Fisher HM-1630-F, 1:100); mouse anti-Arid1a
(Santa Cruz Biotechnology sc-32761, 1:100); mouse anti-p53 (Santa Cruz Biotechnology sc126, 1:50) and rabbit anti-LKB1 (Abcam ab185734 1:100). For immunofluorescence, secondary antibodies were obtained from Abcam and used at 1:300 dilution; samples were mounted with Fluorescence mounting media (Dako, S3023) and imaged on the Olympus Confocal Microscope.
.
Whole Exome Sequencing:
Whole exome sequencing of harvested murine tumors was performed at Johns Hopkins University Next Generation Sequencing (NGS) Core Facility. Briefly, the Agilent SureSelect Mouse exome sequencing kit was used to prepare sequencing libraries and capture annotated exonic sequences. The resulting libraries were sequenced on a HiSeq 2500, and after quality control checks the fastq files were aligned to genome build mm10 with bwa mem 0.7.7. Picard tools 1.118 were used to remove duplicate reads and GATK 3.6 was used for base recalibration.
To call somatic variants, a reference sequence panel of normals was first constructed from C57BL mouse strains, and Mutect2 was used with this panel. Annotation was done with snpEFF and snpSIFT.
RESULTS:

Strategy for virally delivered CRISPR-mediated genome editing in the adult pancreatic epithelium
As a prelude for in vivo gene editing studies we first performed direct injection of AAV containing reporter alleles into the mouse pancreas. To test the differential efficacy of distinct AAV serotypes infecting pancreatic epithelial cell, we injected AAV6-Cre-GFP and AAV8-Cre-GFP into the adult mouse Pancreata (Supplementary Figure. Henceforth, all of our AAV vectors were made using AAV8. Further, in order to avoid spurious
Cre-dependent recombination in the non-epithelial pancreatic tissue including the peritoneum from the injected virus, we deleted the Cre sequence from the original AAV construct, AAV-KPL ( Supplementary Figure.1A) . Instead, we generated p48-Cre +/-; LSL-Cas9 mice as the "workhorse" mouse where Cre recombinase is only expressed in the adult pancreatic epithelium, specifically acinar cells.
Multiplexed CRISPR/Cas9 mediated somatic genome-editing results in autochthonous PDAC harboring diverse genotypes.
A set of six independent AAV8 vectors were generated for injection into the pancreas of p48-Cre +/-;LSL-Cas9 mice, containing the following sgRNAs: (i) AAV-LacZ (control) (ii)AAV-Kras (which included the Kras G12D HDR template and henceforth designated as "K", (iii) AAV-Kras, Trp53 ( henceforth designated as "KP"), (iv)AAV-Kras; Arid1a (henceforth designated as "KA"),
(v) AAV-Kras; Trp53; Lkb1 (henceforth designated as "KPL") and (vi) AAV-Kras;Trp53;Arid1a
(henceforth designated as "KPA"). The schematic of the model development and post-harvest correlative assays are illustrated in Figure 1A . The pancreatic development was monitored in real time by ultrasound as shown in Figure 1B . The survival of the mice injected with the six vectors is depicted in Figure 1C . Excluding the control "LacZ" mice, the mice with "K" and "KA" had the most indolent natural history with no mortality observed at ~100days (at which point these mice were euthanized). In contrast, "KP", "KPA" and "KPL" injected mice had comparable median survival with progression to invasive neoplasia. In the "KPL" injected nice, ultrasound examination demonstrated readily visible tumors as early as eight weeks after injection and these were apparent 1-2 weeks later in "KP" and "KPA" injected mice.
Representative histopathology photomicrographs from the mice injected with various AAV constructs are shown in Histopathological examination of the invasive carcinomas at low magnification often showed normal pancreatic parenchyma adjacent to a region of invasive carcinoma mirroring the "segmental" nature of disease in the human pancreas ( and distinct from the multifocal nature of disease seen in the conventional Cre models) (Supplementary Figure 4A) . While adenocarcinomas were seen with all three cancer forming genotypes ("KP", "KPA" and "KPL") ( Figure 2) , the proportion of adenocarcinomas versus poorly differentiated (sarcomatoid) tumors varied (Supplementary Figure 4B) , with "KPL" and "KPA" resulting predominantly in adenocarcinomas and "KP" in poorly differentiated lesion. These variations in the proportion of histological subtypes for individual genotypes have been well documented with Cre-based models [34], so was not unexpected. In addition to the primary tumor, metastatic adenocarcinomas were observed in a subset of "KPL" and "KPA" injected mice, specifically in the liver and lung (Supplementary Figure 5) .
Correlative studies in CRISPR/Cas9 generated PDAC models
A series of correlative protein expression and sequencing studies were conducted on the harvested tissues from the CRISPR/Cas9 generated PDAC lesions. For example, we confirmed the loss of expression of p53, Arid1a and Lkb1 within the neoplastic cells of tumors harvested from "KPL" and "KA" and virus injected pancreata, respectively (Figure 3) . Although "KA" injected mice did not form invasive carcinomas, partial to complete loss of expression of Arid1a protein was demonstrable in the ADM and mPanIN lesions that resulted in the pancreata (identified based on Sox9 expression) consistent with successful somatic editing of Arid1a loci (Supplementary Figure 6) . As previously noted "KP" mice developed multiple examples of poorly differentiated (sarcomatoid ) carcinomas, and we confirmed the epithelial origin of these cancers by the expression of cytokeratin 19 in the primary tumors (data not shown). Of note , these poorly differentiated PDAC were characterized by loss of membrane E-cadherin and co expression of the mesenchymal marker vimentin, suggesting a phenotype of partial epithelial to mesenchymal transformation (EMT), which has been previously described in aggressive PDAC [35, 36] .
The T7 endonuclease assay serves as a preliminary measure of the efficacy of genome targeting based on the ability of the enzyme to cleave DNA strands that are not perfectly matched due to non-homologous end joining. Representative examples of the T7 endonuclease assay for Kras, Trp53 and Lkb1 from "KPL" and "KPA" tumors are shown in Figure 4A , which demonstrates targeting of sgRNA to the corresponding locus. In contrast to the cancer samples, the control pancreas injected with LacZ sgRNA showed no evidence of genome editing in the T7 endonuclease assay.
In order to confirm the CRISPR/Cas9 mediated genome editing at the nucleotide level, we then performed exome sequencing of tumor derived genomic DNA from "KPL" and "KPA" virus injected pancreata, using reference DNA from a panel of C57/BL mice. In Figure 4B , we demonstrate NGS reads for KRAS, showing replacement of the endogenous locus with the donor template carrying the codon 12 non-synonymous mutation by HDR. Additional "marker" nucleotides (in blue color on sequence read) derived from the exogenous KRAS template (and accounting for synonymous base variations) are seen in the neoplastic DNA, confirming that the Kras G12D mutation observed was not spontaneous but rather derived from the exogenous template by HDR. Since "bulk" tumor DNA was sequenced, we observed a mutant fraction of 9% for the Kras G12D allele suggesting ~20 % neoplastic cellularity. Exome sequencing data also confirmed disruption of three loci (Arid1a, Trp53 and Lkb1), with multiple insertion deletion ("indel") events observed for each gene (Figures 4C, D and E) . This is consistent with independent CRISPR editing events occurring during the initial injection, and the observed PDAC "mass" at necropsy being of oligoclonal origin. The pie charts adjacent to each gene designate an overview of the classes of indel events for each targeted locus (detailed information for individual mouse tumors sequenced is illustrated in Supplementary Figure 7) . The majority of indels were located 1-5bp upstream or downstream of the PAM sequence. The maximum insertion size observed was 15bp and the maximum deletion size observed was 23bp. Overall, between 8-30% of DNA reads (based on underlying neoplastic cellularity and gene of interest) demonstrated unequivocal indels on sequencing.
Finally, we explored whether the resulting tumors had developed secondary mutations of the 12 most commonly altered genes in PDAC, using data collated from the TCGA and ICGC datasets [3, 4] . Besides the CRISPR targeted genes in the corresponding mouse model ( Supplementary   Figure 8) , we did not observe any secondary mutations in genes such as Smad4, Gnas, Rnf43, Kdm6a and Brca2. Importantly, the notable exceptions were Kmt2c (Mll3) and Kmt2d (Mll4), which encode for chromatin regulatory proteins [37] , and demonstrated frameshift mutations or "indels" in subsets of tumors. It is unclear whether these events represented a requirement for tumor progression in these models, given that in the TCGA and ICGC datasets genes encoding for chromatin regulatory proteins are one of the most commonly mutated family of genes [3, 4] .
DISCUSSION:
GEMMs represent the most rigorous preclinical platform for hypothesis testing the functional contribution of recurrent genetic alterations towards multistep pancreatic carcinogenesis, but conventional approaches demonstrate several logistical and temporal challenges, particularly, when complex allelotypes are desired. In this study, we have successfully demonstrated CRISPR-induced somatic gene editing using AAV-mediated direct intra-pancreatic injection of diverse sgRNA combinations for establishing autochthonous PDAC with high efficiency, and for some of the genotypes, relatively short latency to cancer incidence. Specifically, while five distinct sgRNA combinations were used as AAV cargo and all developed mPanINs, three genotypes ("KP", "KPA", and "KPL") resulted in PDAC in the arbitrarily assigned time frame for observation (~3 months), underscoring the importance of the genetic background on the latency of cancer formation. While it is certainly possible that the remaining two genotypes ("K"
and "KA") might eventually develop PDAC on longer follow up, our goal in this initial feasibility study was to keep the time frame for observation relatively short and perform necropsy on any surviving mice at ~3 months. Importantly, all of the resulting PDAC lesions developed on a backdrop of credentialed precursor lesions (mPanINs and IPMNs), and progressed to metastatic disease in a subset of mice, confirming that the autochthonous models we have developed recapitulates the multistep progression seen in conventional Cre-based models. Loss of CRISPR-disrupted protein expression was confirmed in both pre-invasive and invasive neoplastic lesions, and NGS on the resulting tumors validated gene targeting at the sequence level.
The catalogue of genetic alterations targeted using CRISPR sgRNAs in the pancreas were based on the frequency of alterations reported in human PDAC in public databases [3, 4] . For example, KRAS, which is activated by oncogenic mutations in >90% of PDAC, and TP53, which is inactivated by loss of function mutations of homozygous deletions in 75% of PDAC, are obvious choices. In fact, mutations of KRAS are required not only for the cell autonomous effects in cancer progression, but also for the paracrine effects on the tumor microenvironment that create a tumor permissive immune milieu [38, 39] . Somatic mutations of the SWI/SNF complex ARID1A are seen in approximately 8-10% of PDAC, and this DNA binding helicase has been implicated in maintenance of acinar cell identity, and attenuating the progression to a precursor ductal phenotype (acinar ductal metaplasia) on a mutant Kras background [40, 41] . In our series, confirmed loss of Arid1a and expression of mutant Kras in "KA" mice was sufficient to induce mPanINs, but not PDAC within the ~3 month time window. In contrast, addition of Trp53 deletion ("KPA") resulted in PDAC with relatively short latencies, with a greater propensity towards differentiated adenocarcinomas than the poorly differentiated carcinomas observed in "KP" mice alone. Of note, this correlation between ARID1A mutations and histological grade of differentiation has also been reported in other solid cancers, such as endometrial, hepatocellular, and pancreatic carcinomas [42] [43] [44] , suggesting that loss of this epigenetic regulator might promote the acquisition of a ductal (i.e. "differentiated") phenotype in PDAC. Finally, we also targeted Lkb1, which encodes for a serine threonine kinase mutated in several solid cancers. In the pancreas, LKB1 mutations or loss of Lkb1 expression has been described in cystic precursors (IPMNs) [45, 46] , and prior conventional models of conditional Lkb1 loss have demonstrated PDAC arising on the background of cystic neoplasms [47, 48] . In our series, we did not examine "KL" as a dual targeting construct, but "KPL" injected mice developed cystic lesions resembling IPMNs in a subset of cases. Similar to "KPA" mice, "KPL" mice also developed predominantly adenocarcinomas upon progression.
A few important methodological caveats emerged during the course of this study. First, we recognized the AAV8 serotype to be significantly more efficient at viral transduction than AAV6, which is consistent with prior reports of using AAV8 as a delivery vector to the pancreas Kras, by varying the timing of AAV/CRISPR delivery (for example, with sequential injections).
Of interest, NGS studies on the CRISPR-induced PDAC showed that editing events were typically localized within a few bases of the PAM sequence, with individual "bulk" tumors harboring multiple classes of "indels" or frameshift mutations. This is consistent with the CRISPR-induced PDAC being an oligoclonal mix of more than one initiating clonal event, as previously reported [26] . While we did not pursue this particular line of investigation, one can envision that barcoding individual AAV constructs could allow for rigorous interrogation of selectivity in tumor formation and metastatic ability of distinct genomic alterations even at one given locus. The NGS data also revealed a somewhat robust rate of HDR for Kras in the sequenced "bulk" tumors (9% on average across six tumors), which is substantially greater than the 1.8% Kras HDR frequency reported in generating lung cancer models using AAV-mediated delivery of CRISPR [19] . The precise reason for this in unclear, but might represent a higher propensity for HDR in the pancreatic acinar component compared to the pulmonary epithelium, or a greater ability of the AAV8 serotype used in this study to enable HDR in the mouse genome, independent of exonuclease activity, as was recently shown for certain AAV strains [50] . Finally, our sequencing data showed that while several recurrently mutated PDAC-associated genes,
including Smad4, Gnas, Rnf43, Kdm6a and Brca2 did not undergo secondary mutations during PDAC development, two genes in particular -Kmt2c (Mll3) and Kmt2d (Mll4), which encode for chromatin regulatory proteins [37] -did demonstrate recurrent alterations. The encoded proteins, Mll3 and Mll4, are histone methyltransferase enzymes that are part of a so-called COMPASSlike complex responsible for addition of methyl residues to lysine residues on histones, which function as an "activation mark". Loss of function mutations of MLL3 and other COMPASS-like complex proteins is reported in approximately 10% of PDAC, and loss of expression has been associated with better prognosis [37] . We are continuing to explore the relevance of these recurrent non-targeted mutations, including their requirement for tumor formation in the context of other targeted loci using the AAV-CRISPR system.
In summary, we have generated a "workhorse" Ptf1-Cre; LSL-Cas9 mouse that enables the relatively facile interrogation of the functional role of mutated genes in the PDAC landscape, including diverse combinations of targeted alleles using AAV8 as a delivery vector. Our platform precludes the need for a germline mutant Kras allele in the host mouse, and the resulting pancreata demonstrate the full compendium of precursor and invasive lesions observed in human PDAC. This "workhorse" platform will allow investigators to conduct in vivo functional genomics studies and generate reagents, such as cell lines with defined genetic alterations, with considerable efficiency. B. The underlying genotype has an impact on the histology of the resulting PDAC in "KP", "KPL' and "KPA" mice. Thus, the majority of cancers in "KP" mice are poorly differentiated (sarcomatoid) carcinomas, while a smaller proportion are adenocarcinomas. In contrast, "KPA"
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and "KPL" both developed a higher frequency of conventional adenocarcinomas. Cases with no PDAC harbored high-grade PanINs.
Of note, "KA" and "K" mice are not illustrated, as these did not develop cancers in any of the examined cases, although mPanINs and ADMs were observed. 
Supplementary
